AEZS Has Exclusive Agreement to Develop Oral COVID-19 Vaccine

Price already jumped from this news but successful clinical trials could will likely cause the price soar Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg Company secures next step to continue to build-out pipeline of assets. University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. https://finance.yahoo.com/news/aeterna-zentaris-announces-evaluation-potential-123000272.html

back
photo-url-https://api.utradea.com/profile_pictures/60f0ef2f8313f34d019d1cae.jpeg

GeorgeL88

Feb 5, 2021
· POSITION CLOSED

63.89%

Position Return %

1.08

Price When Posted

0.69

Position Return

AEZS

Aeterna Zentaris Inc.

0.63

0.01
1.89%
Current Price

AEZS Has Exclusive Agreement to Develop Oral COVID-19 Vaccine

bullish

Price already jumped from this news but successful clinical trials could will likely cause the price soar

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg

Company secures next step to continue to build-out pipeline of assets.

University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19.

Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.

Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19.

A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial.

https://finance.yahoo.com/news/aeterna-zentaris-announces-evaluation-potential-123000272.html

Comments

Write your comment....

Sign in to comment

read-time
1 min

1.19

Target Price

7/ 10

Confidence

2-6 Months

Timeframe
catalyst icon
Earnings Release
catalyst icon
News
catalyst icon
SEC Filing
catalyst icon
Sentiment
catalyst icon
Other Catalyst

AEZS Channel

Start new chat
next